Consistently, immunoblot and RT-qPCR analysis of cpd10-treated MCL cells revealed a significant reduction of expression of the FOXO1 target genes EBF1, PAX5, and CD79B in comparison with mock-treated control cells (Figure 6, I and J). This evidence concerns the gene PAX5 and mantle cell lymphoma.